- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02543593
Efficacy of Transcranial Direct-Current Stimulation (tDCS) for Provoked Vestibulodynia : a Triple Blind Randomized Controlled Trial (PVD/tDCS)
1. května 2017 aktualizováno: Mélanie Morin, Université de Sherbrooke
Provoked vestibulodynia (PVD) is the most common form of vulvodynia and despite its high prevalence and important sexual, conjugal and psychological deleterious repercussions, effective evidence-based interventions remain limited.
For a high proportion of women, significant pain persists despite the currently available treatments.
Transcranial direct-current stimulation (tDCS) was shown to be effective in various chronic pain conditions.
So far, only one case report study has shown significant pain reduction in women with vulvodynia.
The main goal of this randomized controlled trial is to evaluate the efficacy of tDCS in women with PVD compared to sham tDCS.
Forty women diagnosed with PVD, by a gynecologist following a standardized protocol will be randomized to either active or sham tDCS for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
Outcome measures will be collected at baseline, after treatment and at 3-month follow-up.
The primary outcome is pain during intercourse assessed with a numerical rating scale (NRS).
Secondary measurements focus on sexual function, vestibular pain sensitivity, psychological distress, treatment satisfaction and Patient Global Impression of Change (PGIC).
The investigators expect that active tDCS treatment will significantly reduce pain during intercourse (post-treatment and 3-month follow-up compared to pre-treatment assessment).
This trial will provide important information for determining the efficacy of a novel and promising intervention for women with PVD.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Aktuální)
40
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Quebec
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Centre hospitalier Universitaire de Sherbroke
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
17 let až 45 let (Dítě, Dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Ženský
Popis
Inclusion Criteria:
- Experience moderate to severe pain in at least 90% of attempted sexual intercourse;
- Experience moderate to severe pain during cotton swab test, in one or more regions of the vestibule (minimum of 5/10 on a subjective numeric scale of pain intensity);
- Pain limited to the vestibule during vaginal intercourse and during activities exerting pressure on the vestibule (tampon insertion, tight jeans or pants, cycling, horseback riding);
- Presence of PVD for at least 6 months and diagnosed according to the standardized gynecological examination protocol by one of our staff gynecologists;
- Have a stable sexual partner with regular sexual activity including penetration.
Exclusion Criteria:
- Other pelvic pathology associated with pelvic pain (e.g., deep dyspareunia);
- Chronic pain conditions (e.g. fibromyalgia, low back pain, chronic migraines);
- Use of medication that can influence the perception of pain (eg analgesic, opioids, antiepileptic, muscle relaxant);
- Pregnancy for less than one year and breastfeeding;
- Anterior vulvar or vaginal surgery;
- Refusal to refrain from other treatments one month prior to first treatment study until the last 3-month follow-up assessment;
- Important urogynecologic symptoms (urinary or anal incontinence, urinary urgency, pelvic organ prolapse, active urinary tract or vaginal infection or earlier in the last 3 months, etc.);
- Contraindications to tDCS (e.g. metallic implant in or near the skull, history of epilepsy, pacemaker);
- Previously received tDCS treatment.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Intervention
Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
|
tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex.
In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
Ostatní jména:
|
Falešný srovnávač: Placebo
Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
|
tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex.
In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Pain during intercourse (Numeric rating scale)
Časové okno: Change in the NRS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Pain during intercourse will be assessed using a numeric rating scale (NRS) ranging from 0 to 10, where 0 is no pain at all, and 10 is the worst pain ever.
This method for measuring pain has been shown to detect significant treatment effects in women with PVD and demonstrates a significant positive correlation with other pain intensity measures.
Pain during intercourse is the main symptom of PVD and the one that most interferes with quality of life, hence the most relevant measure of functional outcome (Bergeron et al., 2008; Bergeron et al., 2001; Morin et al., 2010; Morin et al., 2011).
|
Change in the NRS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Pain (McGill-Melzack questionnaire)
Časové okno: Change in the McGill-Melzack scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
The McGill-Melzack questionnaire allows the assessment of sensory, affective and evaluative components of pain.
This world-renowned questionnaire, studied for its validity, reliability and responsiveness to change, is commonly used in RCTs (Bergeron et al., 2001; Melzack, 1975; Davidoff et al., 1987; Hays et al., 1994; Bansal et al., 2009; Moy et al., 2011; Foster et al., 2010).
|
Change in the McGill-Melzack scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Vestibular sensitivity (algometer)
Časové okno: Change in the pain threshold and pain tolerance scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
A gradual pressure (1 to 1000 g) will be applied to three distinct points of the vestibule at the 3, 6 and 9 o'clock positions (Cyr et al., 2014).
Each of these pressure points will be applied randomly (e.g.
3,6,9 or 3,9,6 or 6,9,3.).
During this procedure, each participant will be asked to indicate when they start to feel pain (pain threshold) and subsequently the maximal pressure that can be tolerated (pain tolerance).
Pain intensity is assessed throughout the test using a Computerized Visual analog scale (CoVas).
This assessment has shown good reliability and validity (Cyr et al., 2014).
|
Change in the pain threshold and pain tolerance scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Female Sexual Function Index (FSFI)
Časové okno: Change in the FSFI scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
The Female Sexual Function Index (FSFI) is a multidimensional measure of sexual function evaluating desire, arousal, lubrication, orgasm, satisfaction and pain.
In addition to good psychometric properties (reliability, internal consistency and responsiveness to change (Rosen et al., 2000; Goldfinger et al, 2009), normative data are available for this questionnaire suggesting clinical level of dysfunctions (Wiegel et al., 2005).
|
Change in the FSFI scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Pain Catastrophizing Scale (PCS)
Časové okno: Change in the PCS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (Sullivan, Bishop, & Pivik, 1995), which consists of 13 items measuring exaggerated negative thoughts and feelings about the meaning of pain.
Items are scored on a 5-point scale with the end points (0) not at all and (4) all the time.
The PCS is a reliable and valid measure that has demonstrated a stable factorial structure across clinical and general populations, including a French population (French et al., 2005; Osman et al., 2000; Sullivan, et al., 1995).
|
Change in the PCS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Spielberg State-Trait Anxiety Inventory (IASTA)
Časové okno: Change in the IASTA state and IASTA trait scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Anxiety will be assessed using the Spielberger State-Trait Anxiety Inventory (STAI - (Spielberger, Gorsuch, & Lushene, 1970); ASTA - (Gauthier & Bouchard, 1993)).
The STAI is a 40-item, well-known and widely used measure of state and trait anxiety that has demonstrated very good psychometric properties (Cronbach's alpha State = .93,
Trait = .97)
in various clinical and non-clinical samples including pain populations (Gauthier & Bouchard, 1993; Greenberg & Burns, 2003; Rule & Traver, 1983; Tanaka-Masumi & Kameoka, 1986).
|
Change in the IASTA state and IASTA trait scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Beck Depression Inventory questionnaire (BDI-II)
Časové okno: Change in the BDI scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Depression or depression symptoms will be measured with the Beck Depression Inventory-II (BDI-II).
The BDI-II is comprised of 21 items, with scores for most items ranging from 0 (low intensity) to 3 (high intensity) (Beck, Steer & Brown, 1996; Beck, Steer & Garvin, 1988).
This measure of depression has been validated for use in chronic pain populations (Turner & Romano, 1984).
|
Change in the BDI scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Pain Anxiety Symptoms Scale (PASS-20)
Časové okno: Change in the PASS-20 scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
The Pain Anxiety Symptoms Scale (PASS-20), evaluating fear of pain, also shows good psychometric properties (Coons, Hadjistavropoulos & Asmundson, 2004; McCracken & Dhingra, 2002).
|
Change in the PASS-20 scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Patient's global impression of change (PGIC)
Časové okno: Change in the PGIC scores from 2-week post-treatment to 3-month post-treatment
|
Patient self-reported improvement [scale of 0 (completely dissatisfied) to 10 (completely satisfied)] and treatment satisfaction [scale of 0 (worse) to 10 (complete cure)] will be measured at the 2-week post-treatment and 3-month post-treatment structured interview in order to assess the clinical significance of results.
|
Change in the PGIC scores from 2-week post-treatment to 3-month post-treatment
|
Global Measure of Sexual Satisfaction scale (GMSS)
Časové okno: Change in the GMSS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Sexual satisfaction will be assessed using the Global Measure of Sexual Satisfaction scale, which consists of 5 items assessing global sexual satisfaction.
Internal consistency of this scale is high (alpha = 0.90), as is test-retest reliability (r = 0.84) (Lawrance & Byers, 1998).
|
Change in the GMSS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Užitečné odkazy
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. listopadu 2014
Primární dokončení (Aktuální)
1. června 2016
Dokončení studie (Aktuální)
1. listopadu 2016
Termíny zápisu do studia
První předloženo
4. září 2015
První předloženo, které splnilo kritéria kontroly kvality
4. září 2015
První zveřejněno (Odhad)
7. září 2015
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
2. května 2017
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
1. května 2017
Naposledy ověřeno
1. května 2017
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 14-169
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Active tDCS or Sham tDCS
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Zápis na pozvánkuPoruchy související s látkamiŠpanělsko
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)DokončenoVelká depresivní poruchaSpojené státy
-
Charite University, Berlin, GermanyPhysikalisch-Technische Bundesanstalt Institut Berlin (PTB)DokončenoZdravé starší dospěléNěmecko
-
Charite University, Berlin, GermanyPhysikalisch-Technische Bundesanstalt Institut Berlin (PTB)DokončenoZdravé starší dospěléNěmecko
-
Centre Hospitalier Universitaire de NiceZápis na pozvánkuNeurokognitivní poruchy | ApatieFrancie
-
Mariella EnocNáborMentální anorexie | Poruchy příjmu potravy | Poruchy přejídáníItálie
-
The Hong Kong Polytechnic UniversityNáborElektroencefalografie | Transkraniální stimulace stejnosměrným proudem | Porucha autistického spektraHongkong
-
Charite University, Berlin, GermanyDokončeno
-
Wolnei CaumoDokončenoFibromyalgieBrazílie
-
The Hong Kong Polytechnic UniversityDokončenoKoktavý, dospělý | KoktáníHongkong